Physician profile
Shamim Saeed
NPI 1720186455
$6,404.21
in general payments reported to CMS, 2019-2025
36 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what 86% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $656 · 2021: $992 · 2022: $763 · 2023: $763 · 2024: $1,215 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,074.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,316.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $834.15 | 2019-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals Lp | $632.16 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $526.20 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $478.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $382.38 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $300.06 | 2019-2025 | Steglatro, Belsomra, Capvaxive |
| Abbott Laboratories | $194.55 | 2022-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $177.86 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $171.04 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $147.95 | 2023-2025 | |
| Amarin Pharma, INC. | $131.37 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.09 | 2019-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $115.03 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $114.49 | 2021-2024 | Austedo Xr, Austedo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $106.21 | 2022-2025 | Injectafer |
| Exact Sciences Corporation | $85.49 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $80.98 | 2019-2020 | |
| Abbvie INC. | $63.59 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $61.12 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company Ltd. | $54.82 | 2022 | |
| Idorsia Pharmaceuticals US INC | $51.83 | 2023-2025 | Quviviq, Quviviq |
| Sanofi Pasteur INC. | $44.90 | 2020-2024 | |
| Amgen INC. | $37.00 | 2019-2022 | |
| Phadia US INC. | $19.94 | 2023 | Immunocap |
| Boston Scientific Corporation | $18.33 | 2025 | General - Pain Management |
| Xeris Pharmaceuticals, INC. | $17.77 | 2025 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $17.06 | 2025 | Gemtesa |
| Genentech USA, INC. | $14.43 | 2019 | |
| Redhill Biopharma INC. | $13.74 | 2023 | Talicia |
| Ibsa Pharma INC. | $13.51 | 2023 | Tirosint, Licart |
| Hikma Pharmaceuticals USA | $13.33 | 2019 | |
| Medtronic, INC. | $13.30 | 2024 | Closurefast |
| Allergan, INC. | $12.31 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.74 | 2020 | |
| Eisai INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shamim Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.